文献速递眼整形与眼眶神经眼科

用于评估或矫正上睑下垂的药物:美国眼科学会报告

Pharmacologic Agents Used in the Assessment or Correction of Blepharoptosis: A Report by the American Academy of Ophthalmology.
PubMed 文献 · Ophthalmology · 2025-04-02

本文综述PubMed截至2024年7月的文献,纳入26项研究,评价去氧肾上腺素、可卡因、羟苯丙胺、阿可乐定、萘甲唑啉和羟甲唑啉等药物短期矫正上睑下垂的有效性与安全性。去氧肾上腺素、可卡因和羟苯丙胺仅用于诊室诊断性评估;0.1%盐酸羟甲唑啉滴眼液是美国食品药品管理局唯一批准用于成人获得性上睑下垂治疗的药物,其长期疗效和安全性仍不确定。

要点

  • 去氧肾上腺素、可卡因、羟苯丙胺仅用于诊室评估上睑下垂或霍纳综合征,治疗作用尚不确定。
  • 0.1%盐酸羟甲唑啉滴眼液是美国食品药品管理局唯一批准用于成人获得性上睑下垂的药物。
  • 纳入研究中未报告与治疗相关的严重不良事件;羟甲唑啉长期疗效和安全性仍不确定。

核心结论

  • 去氧肾上腺素、可卡因、羟苯丙胺、阿可乐定、萘甲唑啉和羟甲唑啉可实现上睑下垂的短期矫正。
  • 去氧肾上腺素、可卡因和羟苯丙胺仅在上睑下垂或霍纳综合征的诊室评估背景下被描述,其治疗作用仍不确定。
  • 0.1%盐酸羟甲唑啉滴眼液是美国食品药品管理局唯一批准用于成人获得性上睑下垂治疗的药物。
  • 羟甲唑啉可能需要进行独立验证研究,其长期疗效和安全性数据仍不确定。

研究设计与样本

  • 美国眼科学会报告,通过PubMed数据库检索截至2024年7月的英文文献,检索获得197条引文,26篇文章符合本评估的全部纳入标准。
  • 排除病例报告和小型病例系列;由方法学家小组对每项纳入研究进行证据等级评定。

主要发现

  • 4项研究评为Ⅰ级证据,4项研究评为Ⅱ级证据,18项研究评为Ⅲ级证据。
  • 提供上睑下垂短期改善的药物包括去氧肾上腺素、可卡因、羟苯丙胺、阿可乐定、萘甲唑啉和羟甲唑啉。
  • 去氧肾上腺素、可卡因和羟苯丙胺仅在诊室用于诊断目的。
  • 纳入研究中未报告与治疗相关的严重不良事件。
  • 报告的不良事件包括阿可乐定相关的口干和鼻干,以及羟甲唑啉相关的点状角膜炎和视力模糊、结膜充血、干眼和滴注部位疼痛。

关键数值与推荐

  • 去氧肾上腺素、可卡因、羟苯丙胺、阿可乐定、萘甲唑啉和羟甲唑啉可实现上睑下垂的短期矫正。
  • 0.1%盐酸羟甲唑啉滴眼液是美国食品药品管理局唯一批准用于成人获得性上睑下垂治疗的药物。
  • 去氧肾上腺素、可卡因和羟苯丙胺的治疗作用仍不确定。
  • 羟甲唑啉的长期疗效和安全性数据仍不确定。

临床怎么用

  • 去氧肾上腺素、可卡因和羟苯丙胺可用于诊室评估上睑下垂或霍纳综合征。
  • 0.1%盐酸羟甲唑啉滴眼液是美国食品药品管理局唯一批准用于成人获得性上睑下垂治疗的药物。
  • 羟甲唑啉可能需要进行独立验证研究,其长期疗效和安全性数据仍不确定。

局限性

  • 排除病例报告和小型病例系列。
  • 羟甲唑啉可能需要进行独立验证研究,其长期疗效和安全性数据仍不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To review the literature to determine the efficacy and safety of pharmacologic agents for the short-term (minutes to hours) correction of blepharoptosis. METHODS: A literature search was conducted last in the PubMed database in July 2024 to identify all studies in the English language on the use of pharmacologic agents for the correction of blepharoptosis. The search yielded 197 citations, and 26 articles met all of the inclusion criteria for this assessment. Case reports and small case series were excluded. A panel methodologist then assigned a level of evidence rating for each of the included studies. RESULTS: Four studies were rated level I, 4 studies were rated level II, and 18 studies were rated level III. Medications that provided short-term improvement in blepharoptosis included phenylephrine, cocaine, hydroxyamphetamine, apraclonidine, naphazoline, and oxymetazoline. Phenylephrine, cocaine, and hydroxyamphetamine were used only in the office for diagnostic purposes. No serious, treatment-related adverse events were noted in the studies included in this assessment. Adverse events reported included dry mouth and dry nose with apraclonidine and punctate keratitis and blurred vision, conjunctival hyperemia, dry eye, and instillation site pain with oxymetazoline. CONCLUSIONS: Phenylephrine, cocaine, hydroxyamphetamine, apraclonidine, naphazoline, and oxymetazoline can achieve short-term blepharoptosis correction. Phenylephrine, cocaine, and hydroxyamphetamine have been described only in the context of in-office evaluation of blepharoptosis or Horner syndrome, and their therapeutic role remains uncertain. Oxymetazoline hydrochloride ophthalmic solution 0.1% is the only medication approved by the United States Food and Drug Administration for treatment of acquired blepharoptosis in adults. Independent validation studies may be warranted for oxymetazoline hydrochloride and its long-term efficacy and safety data remain uncertain. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Grob SR, Tao JP, Aakalu VK, et al. Pharmacologic Agents Used in the Assessment or Correction of Blepharoptosis: A Report by the American Academy of Ophthalmology. Ophthalmology. 2025. PMID: 40172501. doi:10.1016/j.ophtha.2025.01.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。